Cosmos Health's Cana Secures Contract Manufacturing Agreement With Australia's Humacology For Up To 500,000 CBD Units Annually

7/9/24 2:08:13 PM ET

Other Pharmaceuticals

Health Care

Get the next $COSM alert in real time by email

Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has secured a contract manufacturing agreement with Australian-based wellness company Humacology.

Humacology is a leading provider of high-quality CBD therapies and pharmaceutical-grade medicinal cannabis to Australian patients and recently received the prestigious Cannabiz Award for Innovation. Humacology is currently embarking on a global expansion drive and has entrusted Cana to manufacture up to 500,000 units of its CBD products.

Get the next $COSM alert in real time by email

Cosmos Health's Cana Secures Contract Manufacturing Agreement With Australia's Humacology For Up To 500,000 CBD Units Annually

Chat with this insight

Recent Analyst Ratings for $COSM

$COSM Financials

Live finance-specific insights

Cosmos Health Issues Letter to Shareholders

Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform

Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market

$COSM Market Insights

Live Market Insights

Cosmos Health's Subsidiary Cana Laboratories Completes Phase I Of Manufacturing Upgrades; Positioned To Generate Over $10M In Recurring Annual Gross Profit By End Of 2025

Cosmos Health Regains Compliance With Nasdaq Minimum Bid Price Rule

Cosmos Health shares are trading higher after the company announced its subsidiary, Cana Laboratories, secured additional contract manufacturing agreements with Provident Pharmaceuticals.

$COSM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

$COSM Press Releases

Fastest customizable press release news feed in the world

Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets

Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M QoQ

Cosmos Health Issues Letter to Shareholders

$COSM SEC Filings

Cosmos Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

SEC Form 10-Q filed by Cosmos Health Inc.

Amendment: SEC Form S-1/A filed by Cosmos Health Inc.

$COSM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$COSM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Siokas Grigorios bought $49,806 worth of shares (60,000 units at $0.83), increasing direct ownership by 4% to 1,394,597 units (SEC Form 4)

Siokas Grigorios bought $158,806 worth of shares (6,712 units at $23.66), increasing direct ownership by 0.51% to 1,334,597 units (SEC Form 4)

Siokas Grigorios bought $49,806 worth of shares (60,000 units at $0.83), increasing direct ownership by 4% to 1,394,597 units (SEC Form 4)

Aslidis Anastasios returned $293 worth of shares to the company (200 units at $1.46), decreasing direct ownership by 0.99% to 20,000 units (SEC Form 4)

Terzis Georgios was granted 51,485 shares, increasing direct ownership by 51% to 152,459 units (SEC Form 4)

$COSM Leadership Updates

Live Leadership Updates

Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor

Cosmos Health Announces the Appointment of Nikos Bardakis, an Experienced Executive in the Pharmaceutical Industry, as Chief Operating Officer

Recent Analyst Ratings for
$COSM

$COSM
Financials

$COSM
Market Insights

$COSM
Large Ownership Changes

$COSM
Press Releases

$COSM
SEC Filings

$COSM
Insider Purchases

$COSM
Insider Trading

$COSM
Leadership Updates